These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 8248084)

  • 41. Glycation of collagen: the basis of its central role in the late complications of ageing and diabetes.
    Paul RG; Bailey AJ
    Int J Biochem Cell Biol; 1996 Dec; 28(12):1297-310. PubMed ID: 9022289
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effects of the Maillard reaction on the physical properties and cell interactions of collagen.
    Avery NC; Bailey AJ
    Pathol Biol (Paris); 2006 Sep; 54(7):387-95. PubMed ID: 16962252
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Glycation and protein crosslinking in the diabetes and ageing pathogenesis].
    Cárdenas-León M; Díaz-Díaz E; Argüelles-Medina R; Sánchez-Canales P; Díaz-Sánchez V; Larrea F
    Rev Invest Clin; 2009; 61(6):505-20. PubMed ID: 20184132
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Kinetics of nonenzymatic glycation of ribonuclease A leading to advanced glycation end products. Paradoxical inhibition by ribose leads to facile isolation of protein intermediate for rapid post-Amadori studies.
    Khalifah RG; Todd P; Booth AA; Yang SX; Mott JD; Hudson BG
    Biochemistry; 1996 Apr; 35(15):4645-54. PubMed ID: 8664253
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Renal catabolism of advanced glycation end products: the fate of pentosidine.
    Miyata T; Ueda Y; Horie K; Nangaku M; Tanaka S; van Ypersele de Strihou C; Kurokawa K
    Kidney Int; 1998 Feb; 53(2):416-22. PubMed ID: 9461101
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Maillard reaction products and chronic diabetic complications].
    Trivin F; Chevenne D; Hautecouverture M
    Ann Biol Clin (Paris); 1999; 57(4):445-54. PubMed ID: 10432367
    [No Abstract]   [Full Text] [Related]  

  • 47. Advanced Maillard reaction end products are associated with Alzheimer disease pathology.
    Smith MA; Taneda S; Richey PL; Miyata S; Yan SD; Stern D; Sayre LM; Monnier VM; Perry G
    Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5710-4. PubMed ID: 8202552
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fructose-mediated non-enzymatic glycation: sweet coupling or bad modification.
    Schalkwijk CG; Stehouwer CD; van Hinsbergh VW
    Diabetes Metab Res Rev; 2004; 20(5):369-82. PubMed ID: 15343583
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes.
    Sugiyama T; Okuno T; Fukuhara M; Oku H; Ikeda T; Obayashi H; Ohta M; Fukui M; Hasegawa G; Nakamura N
    Exp Eye Res; 2007 Sep; 85(3):406-12. PubMed ID: 17678894
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Advanced glycation endproducts and cigarette smoking.
    Nicholl ID; Bucala R
    Cell Mol Biol (Noisy-le-grand); 1998 Nov; 44(7):1025-33. PubMed ID: 9846884
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modification of vimentin: a general mechanism of nonenzymatic glycation in human skin.
    Kueper T; Grune T; Muhr GM; Lenz H; Wittern KP; Wenck H; Stäb F; Blatt T
    Ann N Y Acad Sci; 2008 Apr; 1126():328-32. PubMed ID: 18448838
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS.
    Seftel AD; Vaziri ND; Ni Z; Razmjouei K; Fogarty J; Hampel N; Polak J; Wang RZ; Ferguson K; Block C; Haas C
    Urology; 1997 Dec; 50(6):1016-26. PubMed ID: 9426743
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Advanced glycation end products overload might explain intracellular cobalamin deficiency in renal dysfunction, diabetes and aging.
    Obeid R; Shannan B; Herrmann W
    Med Hypotheses; 2011 Nov; 77(5):884-8. PubMed ID: 21880434
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Advanced glycation end products in children with chronic renal failure and type 1 diabetes.
    Misselwitz J; Franke S; Kauf E; John U; Stein G
    Pediatr Nephrol; 2002 May; 17(5):316-21. PubMed ID: 12042886
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of model Maillard compounds on bone characteristics and functionality.
    Roncero-Ramos I; Delgado-Andrade C; Rufián-Henares JÁ; Carballo J; Navarro MP
    J Sci Food Agric; 2013 Aug; 93(11):2816-21. PubMed ID: 23420603
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Natural compounds containing a catechol group enhance the formation of Nε-(carboxymethyl)lysine of the Maillard reaction.
    Fujiwara Y; Kiyota N; Tsurushima K; Yoshitomi M; Mera K; Sakashita N; Takeya M; Ikeda T; Araki T; Nohara T; Nagai R
    Free Radic Biol Med; 2011 Apr; 50(7):883-91. PubMed ID: 21195168
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacological prevention of cardiovascular aging--targeting the Maillard reaction.
    Aronson D
    Br J Pharmacol; 2004 Aug; 142(7):1055-8. PubMed ID: 15237100
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Protein glycation--clinical and chemical aspects].
    Szymańska U; Boratyński J
    Postepy Hig Med Dosw; 1999; 53(5):689-703. PubMed ID: 10645144
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Maillard reaction in vivo.
    Dyer DG; Blackledge JA; Katz BM; Hull CJ; Adkisson HD; Thorpe SR; Lyons TJ; Baynes JW
    Z Ernahrungswiss; 1991 Feb; 30(1):29-45. PubMed ID: 1858426
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Advances in the Maillard reaction and glycation researches--mainly on the Namiki pathway].
    Namiki M
    Seikagaku; 2003 Jan; 75(1):37-42. PubMed ID: 12645131
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.